Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.



PPMI Enrollment Status

41%
Genetic Cohort Participants
Enrollment Goal: 600

42%
Genetic Registry Participants
Enrollment Goal: ~600

100%
De Novo PD Participants
Enrollment: 423

100%
Control Participants
Enrollment: 196

100%
Subjects with SWEDD
Enrollment: 64

100%
Prodromal Participants
Enrollment: 65

Last Update: March 31, 2016

 

Welcome

The Parkinson’s Progression Markers Initiative (PPMI) is a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.

PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.

PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.

Learn more about Who We Are.

LATEST NEWS FROM PPMI

2016 PPMI Annual Meeting held in New York City

The 2016 PPMI annual meeting took place on May 4-5 in New York City.  The meeting brought together 175 PPMI stakeholders from around the world, including PPMI leadership, site principal investigators, site coordinators and industry partners.  During the two day meeting, there was discussion of the data coming out of PPMI to date, plans for the […]


PPMI Q1 2016 Study Update call

On March 11, Dr. Mark Frasier, Senior Vice President at the Michael J. Fox Foundation, shared an update on the PPMI study. Dr. Frasier summarized some of the key accomplishments of PPMI to date.


Researchers identify biomarker for early cognitive decline in Parkinson’s disease patients using PPMI data

Many patients with Parkinson’s Disease (PD) develop mild cognitive impairment (MCI) or dementia. Identifying biomarkers for cognitive impairment could be instrumental in facilitating both early diagnosis of MCI and developing new cognitive-enhancing treatments. New research using PPMI data published in the Journal of Parkinson’s Disease indicates that lower concentrations of α-synuclein in cerebrospinal fluid (CSF) is associated with reduced performance on several cognitive tests.


Dr. Omar El-Agnaf to use PPMI biospecimens for validation of cerebral spinal fluid α-synuclein species as surrogate biomarkers for Parkinson’s disease

We are excited to announce another recent approval by our Biospecimen Review Committee. Dr. Omar El-Agnaf, Professor at Hamad Bin Khalifa University in Doha, Qatar, will be using PPMI biospecimens for a project entitled: Validation of CSF α-synuclein species as surrogate biomarkers for Parkinson’s disease. Dr. El-Agnaf has recently reported higher levels of the oligomeric […]


Dr. Martin Rabey to use PPMI biospecimens for validation of a blood based gene expression assay

A critical component of PPMI is the standardized, longitudinal collection of biospecimens. Each month the Biospecimen Review Committee examines requests for biospecimens collected through the PPMI study. We are excited to announce approval for Dr. Martin Rabey, the Chief Medical Officer of BioShai Ltd, for a project entitled: Validation of a blood based gene expression […]


Learn More